Trial watch: Monoclonal antibodies in cancer therapy

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Vacchelli, Erika ^a,b,c   Eggermont, Alexander ^b   Galon, Jérôme ^d,e,f,g   Sautès Fridman, Catherine ^d,e,g   Zitvogel, Laurence ^b,h   Kroemer, Guido ^a,d,e,f   Galluzzi, Lorenzo ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut Gustave Roussy   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h University Paris XI   (France)

Author keywords

Bevacizumab; Dalotuzumab; Ipilimumab; Nimotuzumab; Ramucirumab; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; BAVITUXIMAB; BC 8; BEVACIZUMAB; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CETUXIMAB; CH 14 18; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DALOTUZUMAB; DENOSUMAB; DOCETAXEL; GANITUMAB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; NIVOLUMAB; OFATUMUMAB; PANITUMUMAB; PREDNISONE; RAMUCIRUMAB; RITUXIMAB; SILTUXIMAB; TICILIMUMAB; TIGATUZUMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGUS CANCER; EWING SARCOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CARCINOMA; RECTUM CARCINOMA; SARCOMA; SKIN DISEASE; SOLID TUMOR; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME;

EID: 84883219603     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22789     Document Type: Article

References (171)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi. org/10.1038/256495a0
2. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004; 4:153-6; PMID:15040588; http:// dx.doi.org/10.1038/nri1265
3. Zou YR, Gu H, Rajewsky K. Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions. Science 1993; 262:1271-4; PMID:8235658; http://dx.doi.org/10.1126/science. 8235658
4. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313:337-42; PMID:2861567; http://dx.doi.org/10.1056/NEJM198508083130601
5. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
6. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/ onci.1.1.17938
7. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi. org/10.4161/onci.19549
8. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026
9. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology 2012; 1:1111-34; http://dx.doi. org/10.4161/onci.21494
10. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/ onci.20696
11. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: FDAapproved Toll-like receptor agonists for cancer therapy. OncoImmunology 2012; 1:894-907; http://dx.doi. org/10.4161/onci.20931
12. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768 http://dx.doi.org/10.4161/ onci.20459
13. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: Peptide vaccines in cancer therapy. OncoImmunology 2012; 1: In press; http://dx.doi.org/10.4161/onci.22428
14. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial Watch: Prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology 2012; 1: In press; http://dx.doi.org/10.4161/onci.22009
15. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:502-8; PMID:18223225; http://dx.doi. org/10.1158/1078-0432.CCR-07-1509
16. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; http:// dx.doi.org/10.1038/nrd1381
17. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19-28; PMID:16413920; http://dx.doi. org/10.1016/j.immuni.2005.11.010
18. Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103-5; PMID:22720225; http://dx.doi.org/10.4161/ onci.1.1.17963
19. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16:277-306; PMID:21196171; http://dx.doi.org/10.2741/3688
20. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50; PMID:20010915; http://dx.doi. org/10.1038/cr.2009.139
21. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-40; PMID:19730437
22. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42; PMID:11807147; http://dx.doi. org/10.1056/NEJMoa011795
23. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735
24. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 2012; 1:75-7; PMID:22720216; http://dx.doi.org/10.4161/ onci.1.1.17825
25. Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2011; 2:309-16; PMID:21716847; http://dx.doi.org/10.7150/jca.2.309
26. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63; PMID:12011122; http://dx.doi.org/10.1200/ JCO.2002.11.076
27. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and longterm follow-up of the University of Michigan experience. Blood 2000; 96:1259-66; PMID:10942366
28. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:17251916; http://dx.doi.org/10.1038/nrc2051
29. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
30. Bercovici N, Trautmann A. Revisiting the role of T cells in tumor regression. Oncoimmunology 2012; 1:346-50; PMID:22737611; http://dx.doi.org/10.4161/ onci.18800
31. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 2012; 1:544-6; PMID:22754781; http://dx.doi.org/10.4161/onci.19442
32. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012; 11:19-20; PMID:22212672; http://dx.doi.org/10.1038/nrd3629
33. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631-7; PMID:22781692; http://dx.doi.org/10.1038/nbt.2289
34. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol 2011; 9:76-8; PMID:22182971; http://dx.doi. org/10.1038/nrclinonc.2011.198
35. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29:3968-76; PMID:21844504; http://dx.doi.org/10.1200/ JCO.2011.36.2236
36. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage smallcell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29:4436-41; PMID:21969504; http://dx.doi.org/10.1200/JCO.2011.35.6923
37. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, et al. RIBBON-2: a randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29:4286-93; PMID:21990397; http://dx.doi.org/10.1200/ JCO.2010.34.1255
38. Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 2011; 29:4662-8; PMID:22067389; http://dx.doi. org/10.1200/JCO.2011.36.1352
39. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30:34-41; PMID:22124101; http:// dx.doi.org/10.1200/JCO.2011.34.6270
40. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012; 13:172-80; PMID:22178121; http://dx.doi.org/10.1016/ S1470-2045(11)70303-5
41. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473-83; PMID:22204724; http://dx.doi. org/10.1056/NEJMoa1104390
42. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al.; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484-96; PMID:22204725; http://dx.doi.org/10.1056/ NEJMoa1103799
43. Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30:608-15; PMID:22253466; http://dx.doi.org/10.1200/ JCO.2011.38.9650
44. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al.; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie- Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309; PMID:22276820; http:// dx.doi.org/10.1056/NEJMoa1111065
45. Bear HD, Tang G, Rastogi P, Geyer CE Jr., Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366:310-20; PMID:22276821; http://dx.doi. org/10.1056/NEJMoa1111097
46. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13:375-84; PMID:22377126; http://dx.doi. org/10.1016/S1470-2045(12)70049-9
47. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 2012; 30:1476-83; PMID:22430271; http://dx.doi. org/10.1200/JCO.2011.39.6853
48. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534-40; PMID:22454414; http://dx.doi.org/10.1200/ JCO.2011.39.4767
49. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039-45; PMID:22529265; http:// dx.doi.org/10.1200/JCO.2012.42.0505
50. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/ cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509-15; PMID:22665541; http://dx.doi. org/10.1200/JCO.2011.41.5869
51. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011; 29:3126-32; PMID:21730275; http:// dx.doi.org/10.1200/JCO.2010.32.2321
52. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr., et al. Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29:3366-73; PMID:21768458; http://dx.doi. org/10.1200/JCO.2011.35.0868
53. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29:3351-7; PMID:21788566; http://dx.doi.org/10.1200/ JCO.2010.31.4930
54. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273-83; PMID:21991949; http://dx.doi.org/10.1056/ NEJMoa0910383
55. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491-7; PMID:22042958; http://dx.doi.org/10.1200/ JCO.2011.36.7045
56. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncol 2012; 13:25-32; PMID:22153890; http://dx.doi.org/10.1016/S1470-2045(11)70336-9
57. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al.; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44; PMID:22257523; http://dx.doi.org/10.1016/ S1470-2045(11)70397-7
58. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379:633-40; PMID:22257673; http://dx.doi.org/10.1016/S0140-6736(11)61847-3
59. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012; 30:2545-51; PMID:22665540; http://dx.doi. org/10.1200/JCO.2011.37.4546
60. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30:2585-92; PMID:22689807; http://dx.doi.org/10.1200/ JCO.2011.35.6725
61. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al.; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011; 12:773-84; PMID:21724462; http://dx.doi.org/10.1016/S1470-2045(11)70150-4
62. Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2011; 29:3396-401; PMID:21810681; http://dx.doi.org/10.1200/ JCO.2010.33.6594
63. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011; 29:3389-95; PMID:21810687; http:// dx.doi.org/10.1200/JCO.2010.32.1844
64. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29:3559-66; PMID:21844497; http://dx.doi.org/10.1200/ JCO.2010.33.8061
65. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 2011; 29:3990-8; PMID:21931035; http://dx.doi.org/10.1200/JCO.2011.34.8508
66. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al.; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with goodprognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12:1013-22; PMID:21940214; http://dx.doi. org/10.1016/S1470-2045(11)70235-2
67. Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, et al.; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378:1858-67; PMID:22118442; http:// dx.doi.org/10.1016/S0140-6736(11)61040-4
68. Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, et al. Dose-adjusted EPOCHrituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol 2012; 30:830-6; PMID:22312100; http://dx.doi.org/10.1200/ JCO.2011.37.0296
69. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13:716-23; PMID:22677155; http://dx.doi.org/10.1016/S1470-2045(12)70200-0
70. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-31; PMID:22873532; http://dx.doi. org/10.1056/NEJMoa1200920
71. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29:3037-43; PMID:21709185; http://dx.doi.org/10.1200/JCO.2010.33.8038
72. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011; 29:3120-5; PMID:21747084; http:// dx.doi.org/10.1200/JCO.2010.33.4979
73. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29:3419-26; PMID:21810686; http://dx.doi. org/10.1200/JCO.2010.34.1735
74. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42; PMID:22056021; http://dx.doi.org/10.1016/S1470-2045(11)70318-7
75. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapyrefractory, advanced colorectal cancer. J Clin Oncol 2012; 30:1505-12; PMID:22412142; http://dx.doi. org/10.1200/JCO.2011.38.6599
76. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30:1755-62; PMID:22473155; http://dx.doi.org/10.1200/ JCO.2011.38.0915
77. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30:1620-7; PMID:22473163; http://dx.doi.org/10.1200/ JCO.2011.39.6036
78. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615-23; PMID:22665533; http://dx.doi. org/10.1200/JCO.2010.34.5579
79. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
80. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501-8; PMID:22326924; http://dx.doi.org/10.1016/S1470-2045(12)70006-2
81. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an openlabel, phase 2 trial. Lancet Oncol 2012; 13:459-65; PMID:22456429; http://dx.doi.org/10.1016/S1470-2045(12)70090-6
82. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-54; PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032
83. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011; 12:1204-13; PMID:21992852; http://dx.doi. org/10.1016/S1470-2045(11)70242-X
84. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012; 30:1647-55; PMID:22493413; http://dx.doi. org/10.1200/JCO.2011.35.9695
85. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39-46; PMID:22093187; http://dx.doi.org/10.1016/S0140-6736(11)61226-9
86. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
87. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http:// dx.doi.org/10.1056/NEJMoa1200694
88. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13:403-11; PMID:22357140; http://dx.doi.org/10.1016/S1470-2045(11)70386-2
89. Younes A, Kim S, Romaguera J, Copeland A, Farial SdeC, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012; 30:2776-82; PMID:22753910; http://dx.doi.org/10.1200/ JCO.2011.39.4403
90. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the antiinsulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29:4534-40; PMID:22025154; http://dx.doi.org/10.1200/JCO.2010.33.0670
91. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:256-62; PMID:22184397; http://dx.doi. org/10.1200/JCO.2011.37.4355
92. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216
93. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594-600; PMID:22393084; http://dx.doi. org/10.1200/JCO.2011.37.4207
94. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30:1960-5; PMID:22291084; http://dx.doi. org/10.1200/JCO.2011.37.7069
95. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30:1953-9; PMID:22547589; http://dx.doi. org/10.1200/JCO.2011.37.2649
96. Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486:537-40; PMID:22722843
97. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532-6; PMID:22722830
98. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-3; PMID:22281684; http://dx.doi.org/10.1038/ nature10868
99. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005; 11:1551-62; PMID:15746060; http://dx.doi. org/10.1158/1078-0432.CCR-04-1645
100. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
101. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al.; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11; PMID:18846107; http://dx.doi. org/10.1038/cdd.2008.150
102. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID:21527953; http://dx.doi.org/10.1038/ nrm3115
103. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002; 62:6132-40; PMID:12414638
104. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002; 54:1479-84; PMID:12459374; http://dx.doi. org/10.1016/S0360-3016(02)03928-7
105. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17:6888-96; PMID:21989064; http://dx.doi. org/10.1158/1078-0432.CCR-11-1074
106. Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood 2009; 113:5905-10; PMID:19332764; http://dx.doi. org/10.1182/blood-2009-02-205476
107. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, et al. Phase I study of (131) I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237-47; PMID:10438711
108. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical perspective. Pharmacol Ther 2012; 136:334-42; PMID:22940266; http:// dx.doi.org/10.1016/j.pharmthera.2012.07.013
109. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317:1255-60; PMID:21419116; http://dx.doi.org/10.1016/j. yexcr.2011.03.010
110. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
111. Topp MS, Gökbuget N, Zugmaier G, Degenhardt E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 2012; In press; PMID:23024237; http://dx.doi.org/10.1182/blood-2012-07-441030
112. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144:1382-6; PMID:2303711
113. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cellmediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477-86; PMID:22754766; http://dx.doi.org/10.4161/onci.19864
114. Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992; 3:19-24; PMID:1576319
115. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A:261-7; PMID:7718335; http://dx.doi. org/10.1016/0959-8049(94)00413-Y
116. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19:206-17; PMID:8811495; http://dx.doi. org/10.1097/00002371-199605000-00005
117. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, et al. Phase I study of chimeric human/ murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000; 18:4077-85; PMID:11118469
118. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al.; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http:// dx.doi.org/10.1056/NEJMoa0911123
119. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11:21; PMID:21244693; http://dx.doi.org/10.1186/1471-2407-11-21
120. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N Engl J Med 2003; 349:2184-6; PMID:14657423; http://dx.doi.org/10.1056/ NEJMp038156
121. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17:6304-12; PMID:21810918; http://dx.doi.org/10.1158/1078-0432.CCR-10-3336
122. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011; 17:6052-60; PMID:21750201; http://dx.doi.org/10.1158/1078-0432.CCR-10-2979
123. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012; 18:2625-31; PMID:22465830; http://dx.doi. org/10.1158/1078-0432.CCR-12-0061
124. Daher M, Lacouture ME, Rathkopf D, Maki RG, Keohan ML, Gansukh B, et al. Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol 2011; 29:e638-40; PMID:21606420; http://dx.doi. org/10.1200/JCO.2010.34.5116
125. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012; 7:419-26; PMID:22237261; http://dx.doi.org/10.1097/JTO.0b013e31823c5b11
126. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr., Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23:2834-42; PMID:22700995; http://dx.doi.org/10.1093/annonc/ mds142
127. Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70:407-14; PMID:22810805; http://dx.doi.org/10.1007/s00280-012-1924-9
128. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012; 18:3414-27; PMID:22510349; http://dx.doi. org/10.1158/1078-0432.CCR-11-3369
129. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012; 30:1849-56; PMID:22508822; http:// dx.doi.org/10.1200/JCO.2011.37.2359
130. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater J Natl Cancer Inst 2012; 104:975-81; PMID:22761272; http://dx.doi. org/10.1093/jnci/djs258
131. Trial is halted for ganitumab in pancreatic cancer. Cancer Discov 2012; 2:OF4; PMID:23071056; http:// dx.doi.org/10.1158/2159-8290.CD-NB2012-100
132. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010; 11:1354-9; PMID:21154117
133. Karwacz K, Arce F, Bricogne C, Kochan G, Escors D. PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 2012; 1:86-8; PMID:22318430; http://dx.doi.org/10.4161/onci.1.1.17824
134. Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 2012; 1:735-8; PMID:22934265; http://dx.doi.org/10.4161/onci.20823
135. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538
136. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http:// dx.doi.org/10.1182/blood-2007-07-100362
137. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:15118073; http://dx.doi.org/10.1056/ NEJMoa040938
138. Goldberg RM. Cetuximab. Nat Rev Drug Discov 2005; (Suppl): S10-1; PMID:15962524; http://dx.doi. org/10.1038/nrd1728
139. Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov 2006; 5:987-8; PMID:17201026; http://dx.doi.org/10.1038/nrd2204
140. Pollack BP. EGFR inhibitors, MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers Oncoimmunology 2012; 1:71-4; PMID:22720215; http://dx.doi.org/10.4161/ onci.1.1.18073
141. Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV nonsmall cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011; 67:837-45; PMID:20563810; http://dx.doi.org/10.1007/s00280-010-1379-9
142. Choi HJ, Sohn JH, Lee CG, Shim HS, Lee IJ, Yang WI, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011; 71:55-9; PMID:20451284; http://dx.doi.org/10.1016/j.lungcan.2010.04.010
143. Hong J, Peng Y, Liao Y, Jiang W, Wei R, Huo L, et al. Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. Exp Ther Med 2012; 4:151-7; PMID:23060940
144. Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010; 16:1915-23; PMID:20197484; http://dx.doi.org/10.1158/1078-0432.CCR-09-2425
145. Li LF, Wang HQ, Liu XM, Zhang HL, Qiu LH, Qian ZZ, et al. Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2011; 33:626-8; PMID:22325226
146. Ling Y, Chen J, Tao M, Chu X, Zhang X. A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis 2012; 4:58-62; PMID:22295168
147. Qi DL, Wang HQ, Li Y, Huang CB, Wang QS, Xu L, et al. Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2012; 34:152-5; PMID:22780937
148. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012; 13:600-5; PMID:22555809; http://dx.doi. org/10.4161/cbt.19849
149. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012; 30:1138-43; PMID:21170759; http://dx.doi.org/10.1007/s10637-010-9619-8
150. Verduzco-Rodríguez L, Aguirre-González EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cell Ther 2011; 4:182-4; PMID:22198189
151. Yang QY, Shen D, Sai K, Mu YG, Jiang XB, Zhang XH, et al. Nimotuzumab in combination with chemotherapy for patients with malignant gliomas. Zhonghua Zhong Liu Za Zhi 2011; 33:232-5; PMID:21575527
152. You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011; 29:996-1003; PMID:20454832; http://dx.doi.org/10.1007/s10637-010-9444-0
153. Zhao KL, Hu XC, Wu XH, Fu XL, Fan M, Jiang GL. A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs 2012; 30:1585-90; PMID:21901403; http://dx.doi.org/10.1007/s10637-011-9735-0
154. Zhao XY, Guo Y, Zhu YX, Wang Y, Zhu GP, Hu CS, et al. Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2012; 47:536-9; PMID:22932235
155. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10:597-605; PMID:19513949
156. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009; 23:289-304; PMID:19754219; http://dx.doi. org/10.2165/11317600-000000000-00000
157. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-7; PMID:20048182; http:// dx.doi.org/10.1200/JCO.2009.23.7537
158. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol MA. A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design. Clin Lung Cancer 2012; 13:505-9; PMID:22853980; http:// dx.doi.org/10.1016/j.cllc.2012.06.007
159. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I doseescalating study. Br J Haematol 1998; 102:783-90; PMID:9722307; http://dx.doi.org/10.1046/j.1365-2141.1998.00835.x
160. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/ prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48:85-93; PMID:22129890; http:// dx.doi.org/10.1016/j.ejca.2011.10.014
161. Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2012; PMID:22828917; http://dx.doi.org/10.1007/ s10637-012-9857-z
162. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011; 71:1455-65; PMID:21321981; http:// dx.doi.org/10.1002/pros.21362
163. Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG. Targeting TRAIL death receptors. Curr Opin Pharmacol 2008; 8:433-9; PMID:18625341; http://dx.doi.org/10.1016/j.coph.2008.06.011
164. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335-46; PMID:10690508
165. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008; 19:1060-7; PMID:18304965; http:// dx.doi.org/10.1093/annonc/mdn015
166. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25:13-9; PMID:20187792; http:// dx.doi.org/10.1089/cbr.2009.0673
167. Gulley JL, Dahut WL. Future directions in tumor immunotherapy: CTLA4 blockade. Nat Clin Pract Oncol 2007; 4:136-7; PMID:17327854; http://dx.doi. org/10.1038/ncponc0749
168. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326-33; PMID:22737608; http://dx.doi.org/10.4161/onci.18852
169. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012; 30:322-8; PMID:22184371; http:// dx.doi.org/10.1200/JCO.2011.37.5394
170. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012; 61:1137-47; PMID:22210552; http://dx.doi.org/10.1007/s00262-011-1193-1
171. Abès R, Teillaud JL. Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev 2011; 30:111-24; PMID:21267767; http://dx.doi. org/10.1007/s10555-011-9282-3.